UroGen Pharma (URGN) Enterprise Value (2017 - 2026)

UroGen Pharma (URGN) has 11 years of Enterprise Value data on file, last reported at -$140.3 million in Q1 2026.

• Quarterly Enterprise Value rose 28.39% year-over-year to -$140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$140.3 million (up 28.39% YoY) and the FY2025 annual result came in at -$120.5 million, up 49.11% from the prior year.
• Enterprise Value retreated to -$140.3 million in Q1 2026, from -$120.5 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$47.3 million in Q2 2023 to a low of -$249.6 million in Q3 2024.
• A 5-year average of -$143.4 million and a median of -$137.0 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2023 — Enterprise Value surged 52.32% — and 2024, when it plunged 409.67%.
• Tracing URGN's Enterprise Value over 5 years: stood at -$100.0 million in 2022, then tumbled by 37.02% to -$137.0 million in 2023, then slumped by 72.8% to -$236.7 million in 2024, then jumped by 49.11% to -$120.5 million in 2025, then dropped by 16.45% to -$140.3 million in 2026.
• The last three Enterprise Value figures came in at -$140.3 million (Q1 2026), -$120.5 million (Q4 2025), and -$127.0 million (Q3 2025), per Business Quant data.